We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Phase 3 open-label trial evaluated atogepant's effectiveness on migraine prevention in Japanese participants, suggesting its potential as a long-term treatment.
NCT04437433; https://clinicaltrials.gov/study/NCT04437433.
No takes yet. Share an insight, caveat, or question.
Matsumori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: